Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

A team of Northwestern investigators has discovered novel molecular underpinnings of a common oncogenic mutation in cancer, ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

Explore opportunities in protein engineering to innovate therapeutic and industrial applications. Enhance your skills in molecular biology and protein chemistry to develop cutting-edge protein-based ...

Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

A newly discovered nuclear role for HSL reveals how imbalances in its location within fat cells may contribute to both ...

Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 3 ...

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...

The global regenerative medicine market is poised for remarkable expansion, expected to record a compound annual growth rate (CAGR) of around 17% during the forecast period. This surge is primarily ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

Researchers from the UK and Germany have announced to have developed pigs that are resistant to Classical Swine Fever.